Legal & General Group
DNTH icon

Legal & General Group’s Dianthus Therapeutics DNTH Stock Holding History

Legal & General Group’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.15M Buy
32,331
+10,704
+49% +$935K ﹤0.01% 1790
2026
Q1 		$1.81M Buy
21,627
+8,037
+59% +$465K ﹤0.01% 1951
2025
Q4 		$560K Buy
13,590
+12,093
+808% +$469K ﹤0.01% 2396
2025
Q3 		$58.9K Sell
1,497
-332
-18% -$8.48K ﹤0.01% 2699
2025
Q2 		$34.1K Sell
1,829
-2,062
-53% -$38.7K ﹤0.01% 2807
2025
Q1 		$70.6K Sell
3,891
-8,428
-68% -$186K ﹤0.01% 2693
2024
Q4 		$269K Buy
12,319
+2,363
+24% +$60.8K ﹤0.01% 2626
2024
Q3 		$273K Buy
9,956
+1,902
+24% +$53K ﹤0.01% 2628
2024
Q2 		$207K Buy
+8,054
New +$194K ﹤0.01% 2660
2022
Q3 		– Sell
-149
Closed -$3K – 3464
2022
Q2 		$3K Sell
149
-44
-23% -$1.09K ﹤0.01% 3474
2022
Q1 		$9K Hold
193
– – ﹤0.01% 3422
2021
Q4 		$14K Hold
193
– – ﹤0.01% 3378
2021
Q3 		$22K Hold
193
– – ﹤0.01% 3242
2021
Q2 		$30K Buy
193
+52
+37% +$9.55K ﹤0.01% 3132
2021
Q1 		$27K Sell
141
-12
-8% -$2.02K ﹤0.01% 3021
2020
Q4 		$19K Hold
153
– – ﹤0.01% 3107
2020
Q3 		$17K Sell
153
-14
-8% -$1.66K ﹤0.01% 3019
2020
Q2 		$20K Sell
167
-39
-19% -$5.5K ﹤0.01% 3065
2020
Q1 		$21K Sell
206
-45
-18% -$8.34K ﹤0.01% 2888
2019
Q4 		$61K Buy
251
+48
+24% +$8.97K ﹤0.01% 2741
2019
Q3 		$33K Hold
203
– – ﹤0.01% 2916
2019
Q2 		$48K Buy
203
+51
+34% +$12.6K ﹤0.01% 2789
2019
Q1 		$40K Buy
152
+109
+253% +$18.8K ﹤0.01% 2787
2018
Q4 		$4K Hold
43
– – ﹤0.01% 3350
2018
Q3 		$8K Buy
+43
New +$9.05K ﹤0.01% 3342

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Legal & General Group's DNTH Position: Q2 2026 in Review

Legal & General Group increased its Dianthus Therapeutics (DNTH) stake by 49% in Q2 2026, buying an estimated $935K and bringing the position to 32,331 shares worth $3.15M. The position accounts for ﹤0.01% of the portfolio, ranked #1790.

Legal & General Group first reported a position in DNTH in Q3 2018 and has held it in 25 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Legal & General Group held 32,331 shares of Dianthus Therapeutics worth $3.15M as of Q2 2026.
  • Legal & General Group bought 10,704 Dianthus Therapeutics shares in Q2 2026, an estimated $935K.
  • Dianthus Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #1790 holding.
  • Legal & General Group first reported a position in Dianthus Therapeutics in Q3 2018 and has held it in 25 quarters since.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.